MC4DD · Macrocycles for Drug Discovery

Lines connect the coordinator with its partners.

Project objective

Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe.New drug modalities such as macrocycles are expected to be a key enabling technology for this strategic perspective. The goal of MC4DD is to train the next generation of European medicinal chemists in a multidisciplinary environment to promote European drug discovery competitiveness, directly by advancing knowhow on macrocycles and long-term via the skills carried on by the researchers trained in the doctoral network.

Original text from CORDIS.

Participants

• TECHNISCHE UNIVERSITAT DARMSTADT · DarmstadtCoordinatorGermany
• ABBVIE DEUTSCHLAND GMBH & CO KG · WiesbadenGermany
• ANALYTICON DISCOVERY GMBH · PotsdamGermany
• ASTRAZENECA AB · SodertaeljeSweden
• Bayer AG · LeverkusenGermany
• ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE · LausanneSwitzerland
• EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichSwitzerland
• ENAMINE GERMANY GMBH · Frankfurt am MainGermany
• F. HOFFMANN-LA ROCHE AG · BaselSwitzerland
• JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainGermany
• NOVO NORDISK A/S · BagsvaerdDenmark
• SANOFI-AVENTIS DEUTSCHLAND GMBH · Frankfurt Am MainGermany
• SELVITA DOO · ZagrebCroatia
• THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGEUnited Kingdom
• UKRORGSYNTEZ LTD · KYIVUkraine
• UNIVERSITA DEGLI STUDI DI TORINO · TorinoItaly
• UNIVERSITEIT LEIDEN · LeidenNetherlands
• UNIVERSITY COLLEGE LONDON · LondonUnited Kingdom
• UNIVERSITY OF YORK · YORK NORTH YORKSHIREUnited Kingdom
• UPPSALA UNIVERSITET · UppsalaSweden

Links

• View on CORDIS
• DOI: 10.3030/101168916